Intézmény

Dicle University

Diyarbakır, TörökországHonlap

Más néven: Dicle Üniversitesi · Zanîngeha Dîcleyê

30futó vizsgálat
8lezárt vizsgálat
19 238publikáció (OpenAlex)

Futó vizsgálatok

Még nem toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· 3. fázis· Eli Lilly and Company· Forrás
Még nem toboroz
Diet and WB-EMS Effects in Obesity
NCT07562724· Firat University· Forrás
Még nem toboroz
Turkish Chronic Total Occlusion Percutaneous Coronary Intervention Registry
NCT07761624· Ahmet Seyfeddin Gürbüz· Forrás
Toboroz
Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
NCT07459426· Yaşar Bayındır, MD· Forrás
Toboroz
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Toboroz
Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)
NCT07737340· Yaşar Bayındır, MD· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· 3. fázis· Summit Therapeutics· Forrás
Fut, nem toboroz
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672· 3. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944· 3. fázis· Eli Lilly and Company· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Lezárult
NMES Plus Hypocaloric Diet: Body Composition, Cardiometabolic Markers, Irisin and Betatrophin in Women With Obesity
NCT07675382· Firat University· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
NCT07304843· 1/2. fázis· Umecrine Cognition AB· Forrás
Lezárult
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797· 2/3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT04513925· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
NCT03777657· 3. fázis· BeiGene· Forrás

Regiszterbeli névváltozatok (11)

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

Dicle Üniversitesi
Diyarbakır, 21200
15 vizsgálat
Dicle University Faculty of Medicine
Diyarbakır, 21280
10 vizsgálat
Dicle University, Medical Faculty
Diyarbakır, 21080
4 vizsgálat
Dicle Üniversitesi
Sur, Diyarbakır 21200
2 vizsgálat
- NCT07186101LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
  Contact: Kendal Yalcin (principal investigator)
- NCT04255433A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Dicle Üniversitesi (Site 1654)
Diyarbakır, 21200
1 vizsgálat
- NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
  Contact: Study Coordinator
Dicle Üniversitesi (Site 2102)
Diyarbakır, 21280
1 vizsgálat
- NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  Contact: Study Coordinator
Dicle University
Diyarbakır
1 vizsgálat
- NCT07562724Diet and WB-EMS Effects in Obesity
  Contact: Feray Cagiran Yilmaz, assistant professor
Dicle University
Sur, Diyarbakır 21280
1 vizsgálat
- NCT05899608Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Dicle University, Department of Nutrition and Dietetics
Diyarbakır
1 vizsgálat
- NCT07675382NMES Plus Hypocaloric Diet: Body Composition, Cardiometabolic Markers, Irisin and Betatrophin in Women With Obesity
Dicle University Faculty of Medicine Department of Gastroenterology
Diyarbakır, 21280
1 vizsgálat
- NCT07304843A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
Dicle University - Medical Faculty Campus
Diyarbakır, 21200
1 vizsgálat
- NCT05352672Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

Hepatitis B (krónikus)9 munka · 1 vizsgálat
Nephrotic syndrome6 munka · 0 vizsgálat
IgA-nefropátia5 munka · 0 vizsgálat
Turner syndrome3 munka · 0 vizsgálat

Intézményadatok: ROR 0257dtg16 (CC0-1.0)Frissítve: 2026. nov. 14.

Hibát jelzek